Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:rifampin
gptkb:rifampicin |
| gptkbp:activities |
inhibits cell wall synthesis
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Myambutol
|
| gptkbp:can_be_used_with |
gptkb:isoniazid
gptkb:pyrazinamide gptkb:rifampicin |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pregnancy
severe renal impairment optic neuritis lactation |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:discovered_by |
gptkb:1961
|
| gptkbp:dosage_form |
gptkb:tablet
15 mg/kg/day |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
ethambutol
|
| gptkbp:ingredients |
C10 H12 N2 O5
|
| gptkbp:interacts_with |
antacids
aluminum hydroxide other antitubercular drugs |
| gptkbp:is_atype_of |
J04 A K01
|
| gptkbp:is_available_in |
tablets
suspension |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_effective_against |
fungal infections
viral infections non-tuberculous mycobacterial infections bacterial infections other than tuberculosis |
| gptkbp:is_monitored_by |
renal function
visual acuity uric acid levels |
| gptkbp:is_used_for |
treatment of tuberculosis
|
| gptkbp:lifespan |
3 to 4 hours
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:metabolism |
primarily renal
|
| gptkbp:pharmacokinetics |
well absorbed orally
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
dizziness
headache nausea fever vomiting rash peripheral neuropathy loss of appetite gout optic neuritis visual disturbances hyperuricemia |
| gptkbp:suitable_for |
children under 6 years
patients with visual impairment |
| gptkbp:treatment |
multidrug-resistant tuberculosis
|
| gptkbp:type_of |
542-36-3
|
| gptkbp:used_in |
TB control programs
DOTS therapy |